Skip to main navigation Skip to search Skip to main content

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter EVOLUTION study

  • S. K. Kumar
  • , I. Flinn
  • , S. J. Noga
  • , P. Hari
  • , R. Rifkin
  • , N. Callander
  • , M. Bhandari
  • , J. L. Wolf
  • , C. Gasparetto
  • , A. Krishnan
  • , D. Grosman
  • , J. Glass
  • , E. A. Sahovic
  • , H. Shi
  • , I. J. Webb
  • , P. G. Richardson
  • , S. V. Rajkumar

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter EVOLUTION study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science